This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.
Close
Close
Close
Close
Close
Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

Close

Theramex News

Theramex news

Stay up to date with the latest news from Theramex.

17 June 2022

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids

Read more

14 April 2022

Theramex UK Stock Update

Read more

28 March 2022

A consortium of Carlyle and PAI Partners to acquire Theramex from CVC Funds

Read more

21 March 2022

Theramex supports the IOF SCOPE 2021 recommendations and call to action to address the inequalities in Osteoporosis care across Europe

Read more

28 February 2022

Theramex Statement: Russia-Ukraine Crisis

Read more

10 February 2022

Theramex Announces Licensing Agreement with ObsEva for the Commercialisation of Linzagolix for the Treatment of Uterine Fibroids

Read more